SCHEMBL1096715

SCHEMBL1096715

CC(C)N(OP(OCCC#N)ON(C(C)C)C(C)C)C(C)C

nearest known ligand 0.30

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
TSHR P16473 1/20 0.30
NLRP3 Q96P20 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9549066 0.96 TSHR (0.30) TSHRNLRP3
SCHEMBL1500489 0.90
SCHEMBL1589779 0.81
SCHEMBL442366 0.81
SCHEMBL3503381 0.81
SCHEMBL6231122 0.78
SCHEMBL9792927 0.76
SCHEMBL17689313 0.74 NLRP3 (0.37) TSHRNLRP3
SCHEMBL6325642 0.74 TSHR (0.33) TSHR
SCHEMBL1500279 0.73 ALDH1A1 (0.41) TSHRNLRP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125413-A1 UNIVERSAL SOLID SUPPORTS AND PHOSPHORAMIDITE BUILDING BLOCKS FOR OLIGONUCLEOTIDE SYNTHESIS AM CHEMICALS LLC (US) 2026-05-07 US disclosed
US-12397013-B2 Extrahepatic delivery ALNYLAM PHARMACEUTICALS, INC. (US) 2025-08-26 US disclosed
EP-4577539-A1 UNIVERSAL SOLID SUPPORTS AND PHOSPHORAMIDITE BUILDING BLOCKS FOR OLIGONUCLEOTIDE SYNTHESIS AM Chemicals Llc (US) 2025-07-02 EP disclosed
US-20240358738-A1 EXTRAHEPATIC DELIVERY BANK OF AMERICA, N.A. 2024-10-31 US disclosed
US-12005074-B2 Extrahepatic delivery ALNYLAM PHARMACEUTICALS, INC. (US) 2024-06-11 US disclosed
WO-2024044792-A1 UNIVERSAL SOLID SUPPORTS AND PHOSPHORAMIDITE BUILDING BLOCKS FOR OLIGONUCLEOTIDE SYNTHESIS AM CHEMICALS LLC (US) 2024-02-29 WO disclosed
US-20240009225-A1 EXTRAHEPATIC DELIVERY BANK OF AMERICA, N.A. 2024-01-11 US disclosed
US-20230086177-A1 PROCESS FOR PREPARING POLYETHER CARBONATE POLYOLS COVESTRO DEUTSCHLAND AG (DE) 2023-03-23 US disclosed
US-20230069332-A1 PROCESS FOR PRODUCING POLYETHER CARBONATE POLYOLS COVESTRO DEUTSCHLAND AG (DE) 2023-03-02 US disclosed
US-20220411578-A1 PROCESS FOR PRODUCING POLYETHER CARBONATE POLYOLS COVESTRO INTELLECTUAL PROPERTY GMBH & CO. KG (DE) 2022-12-29 US disclosed
US-5914396-A 2'-O-modified nucleosides and phosphoramidites ISIS PHARMACEUTICALS, INC. (US) 1999-06-22 US disclosed
US-5856466-A Process for the preparation of 2'-O-alkyl purine phosphoramidites ISIS PHARMACEUTICALS, INC. (US) 1999-01-05 US disclosed
US-5646265-A Process for the preparation of 2'-O-alkyl purine phosphoramidites ISIS PHARMCEUTICALS, INC. (US) 1997-07-08 US disclosed
EP-0728139-A1 AMINE-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES ISIS PHARMACEUTICALS, INC. (US) 1996-08-28 EP disclosed
US-5506351-A Process for the preparation of 2'-O-alkyl guanosine and related compounds ISIS PHARMACEUTICALS (US) 1996-04-09 US disclosed
EP-0651759-A4 NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF. ISIS PHARMACEUTICALS INC (US) 1995-10-25 EP disclosed
EP-0651759-A1 NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF ISIS PHARMACEUTICALS, INC. (US) 1995-05-10 EP disclosed
WO-1995006659-A1 AMINE-DERIVATIZED NUCLEOSIDES AND OLIGONUCLEOSIDES ISIS PHARMACEUTICALS, INC. (US) 1995-03-09 WO disclosed
WO-1994002501-A1 NOVEL 2'-O-ALKYL NUCLEOSIDES AND PHOSPHORAMIDITES PROCESSES FOR THE PREPARATION AND USES THEREOF ISIS PHARMACEUTICALS, INC. (US) 1994-02-03 WO disclosed
US-5179200-A N4-(3-PHENYLPROPRIONYL)-2'-DEOXYCYTIDINE COMMISSARIAT A L'ENERGIE ATOMIQUE (FR) 1993-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240358738-A1 EXTRAHEPATIC DELIVERY RNASE1, SLC10A1, FABP1 TSHR 662/4885NLRP3 4082/4885
US-12005074-B2 Extrahepatic delivery RNASE1, SLC10A1, FABP1 TSHR 662/4885NLRP3 4082/4885
US-20240009225-A1 EXTRAHEPATIC DELIVERY RNASE1, SLC10A1, FABP1 TSHR 662/4885NLRP3 4082/4885
US-20260125413-A1 UNIVERSAL SOLID SUPPORTS AND PHOSPHORAMIDITE BUILDING BLOCKS FOR OLIGONUCLEOTIDE SYNTHESIS SSU72, NSUN2, POLR2H TSHR 2360/4885NLRP3 4734/4885
US-12397013-B2 Extrahepatic delivery RNASE1, LDLR, HAVCR2 TSHR 885/4885NLRP3 4022/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.